No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

No­vo Nordisk con­tin­ues to sling obe­si­ty drug part­ner­ships. Its lat­est biotech of choice is Septer­na, which will help the Dan­ish phar­ma make oral small mol­e­cules …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER